Acasă › Leucemie mieloasă acută › Arkansas › Little Rock
Studii clinice pentru Leucemie mieloasă acută în Little Rock, AR
13 studii pentru Leucemie mieloasă acută caută participanți în și în jurul orașului Little Rock (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
În curs de recrutareFaza 2
- University of Arkansas for Medical Sciences, Little Rock
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- CARTI Cancer Center, Little Rock
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- University of Arkansas for Medical Sciences, Little Rock
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
În curs de recrutareFaza 3
- University of Arkansas at Little Rock, Little Rock
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- University of Arkansas for Medical Sciences, Little Rock
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- University of Arkansas for Medical Sciences, Little Rock
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
În curs de recrutareFaza 2
- University of Arkansas for Medical Sciences, Little Rock
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
În curs de recrutareFaza 3
- Arkansas Children's Hospital, Little Rock
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
În curs de recrutareFaza 3
- Arkansas Children's Hospital, Little Rock
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
În curs de recrutareFaza 1/2
- Arkansas Children's Hospital, Little Rock
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
În curs de recrutareFaza 3
- Arkansas Children's Hospital, Little Rock
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
În curs de recrutareStudiu observațional
- Arkansas Children's Hospital, Little Rock
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
În curs de recrutareFaza 1
- Arkansas Children's Hospital, Little Rock
Studii pentru Leucemie mieloasă acută în alte orașe
- Houston, TX85 studii
- New York City, NY51 studii
- Boston, MA44 studii
- Seattle, WA41 studii
- Baldwin Park, CA40 studii
- Columbus, OH35 studii
- Philadelphia, PA34 studii
- Durham, NC33 studii
- Atlanta, GA31 studii
- Tampa, FL29 studii
- Chicago, IL26 studii
- Portland, OR25 studii
Alte studii în Little Rock
- Schizofrenie19 studii
- Cancer (toate tipurile)14 studii
- Tulburare depresivă majoră14 studii
- Cancer pulmonar cu celule non-pătrate13 studii
- Obezitate11 studii
- Cancer endometrial10 studii
- Depresie10 studii
- Diabet de tip 210 studii
- Cancer pulmonar9 studii
- Boli cardiovasculare9 studii
- Cancer de vezică urinară9 studii
- Insuficiență cardiacă9 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.